A citation-based method for searching scientific literature

Raphael Bueno, Eric W Stawiski, Leonard D Goldstein, Steffen Durinck, Assunta De Rienzo, Zora Modrusan, Florian Gnad, Thong T Nguyen, Bijay S Jaiswal, Lucian R Chirieac, Daniele Sciaranghella, Nhien Dao, Corinne E Gustafson, Kiara J Munir, Jason A Hackney, Amitabha Chaudhuri, Ravi Gupta, Joseph Guillory, Karen Toy, Connie Ha, Ying-Jiun Chen, Jeremy Stinson, Subhra Chaudhuri, Na Zhang, Thomas D Wu, David J Sugarbaker, Frederic J de Sauvage, William G Richards, Somasekar Seshagiri. Nat Genet 2016
Times Cited: 455







List of co-cited articles
740 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Julija Hmeljak, Francisco Sanchez-Vega, Katherine A Hoadley, Juliann Shih, Chip Stewart, David Heiman, Patrick Tarpey, Ludmila Danilova, Esther Drill, Ewan A Gibb,[...]. Cancer Discov 2018
258
55

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia,[...]. Lancet 2021
232
33

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold,[...]. J Clin Oncol 2003
30

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
Matthew Bott, Marie Brevet, Barry S Taylor, Shigeki Shimizu, Tatsuo Ito, Lu Wang, Jenette Creaney, Richard A Lake, Maureen F Zakowski, Boris Reva,[...]. Nat Genet 2011
461
29

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Gérard Zalcman, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Olivier Molinier, Romain Corre, Isabelle Monnet, Valérie Gounant,[...]. Lancet 2016
503
22

Novel insights into mesothelioma biology and implications for therapy.
Timothy A Yap, Joachim G Aerts, Sanjay Popat, Dean A Fennell. Nat Rev Cancer 2017
186
22

Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.
Yuna Blum, Clément Meiller, Lisa Quetel, Nabila Elarouci, Mira Ayadi, Danisa Tashtanbaeva, Lucile Armenoult, François Montagne, Robin Tranchant, Annie Renier,[...]. Nat Commun 2019
69
30

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Sylvie Lantuejoul, Pascal Dô, Olivier Bylicki, Isabelle Monnet, Romain Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez,[...]. Lancet Oncol 2019
228
21

Germline BAP1 mutations predispose to malignant mesothelioma.
Joseph R Testa, Mitchell Cheung, Jianming Pei, Jennifer E Below, Yinfei Tan, Eleonora Sementino, Nancy J Cox, A Umran Dogan, Harvey I Pass, Sandra Trusa,[...]. Nat Genet 2011
634
20

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo, Juliann Chmielecki, Chandra Goparaju, Adriana Heguy, Igor Dolgalev, Michele Carbone, Sara Seepo, Matthew Meyerson, Harvey I Pass. Cancer Res 2015
196
19

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.
Hedy L Kindler, Nofisat Ismaila, Samuel G Armato, Raphael Bueno, Mary Hesdorffer, Thierry Jahan, Clyde Michael Jones, Markku Miettinen, Harvey Pass, Andreas Rimner,[...]. J Clin Oncol 2018
202
18

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
Michele Carbone, Prasad S Adusumilli, H Richard Alexander, Paul Baas, Fabrizio Bardelli, Angela Bononi, Raphael Bueno, Emanuela Felley-Bosco, Francoise Galateau-Salle, David Jablons,[...]. CA Cancer J Clin 2019
156
15

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Evan W Alley, Juanita Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf, Bilal Piperdi, Emilie van Brummelen. Lancet Oncol 2017
299
14


Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).
Morihito Okada, Takashi Kijima, Keisuke Aoe, Terufumi Kato, Nobukazu Fujimoto, Kazuhiko Nakagawa, Yuichiro Takeda, Toyoaki Hida, Kuninobu Kanai, Fumio Imamura,[...]. Clin Cancer Res 2019
118
14

High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
Masaki Nasu, Mitsuru Emi, Sandra Pastorino, Mika Tanji, Amy Powers, Hugh Luk, Francine Baumann, Yu-An Zhang, Adi Gazdar, Shreya Kanodia,[...]. J Thorac Oncol 2015
189
13

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Josine Quispel-Janssen, Vincent van der Noort, Jeltje F de Vries, Marion Zimmerman, Ferry Lalezari, Erik Thunnissen, Kim Monkhorst, Robert Schouten, Laurel Schunselaar, Maria Disselhorst,[...]. J Thorac Oncol 2018
138
13

Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.
Lisa Quetel, Clément Meiller, Jean-Baptiste Assié, Yuna Blum, Sandrine Imbeaud, François Montagne, Robin Tranchant, Julien de Wolf, Stefano Caruso, Marie-Christine Copin,[...]. Mol Oncol 2020
34
38

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Maria J Disselhorst, Josine Quispel-Janssen, Ferry Lalezari, Kim Monkhorst, Jeltje F de Vries, Vincent van der Noort, Emmy Harms, Sjaak Burgers, Paul Baas. Lancet Respir Med 2019
124
13

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim Aerts, Susana Cedres Perez, Alessandra Bearz, Kristiaan Nackaerts, Dean A Fennell, Dariusz Kowalski, Anne S Tsao,[...]. Lancet Oncol 2017
245
12

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Aliya Noor Husain, Thomas V Colby, Nelson G Ordóñez, Timothy Craig Allen, Richard Luther Attanoos, Mary Beth Beasley, Kelly Jo Butnor, Lucian R Chirieac, Andrew M Churg, Sanja Dacic,[...]. Arch Pathol Lab Med 2018
265
11

Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.
Nicolas Alcala, Lise Mangiante, Nolwenn Le-Stang, Corinne E Gustafson, Sandrine Boyault, Francesca Damiola, Karine Alcala, Marie Brevet, Françoise Thivolet-Bejui, Cécile Blanc-Fournier,[...]. EBioMedicine 2019
31
35

Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Raffit Hassan, Anish Thomas, John J Nemunaitis, Manish R Patel, Jaafar Bennouna, Franklin L Chen, Jean-Pierre Delord, Afshin Dowlati, Samith T Kochuparambil, Matthew H Taylor,[...]. JAMA Oncol 2019
83
13

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Namrata S Patil, Luisella Righi, Hartmut Koeppen, Wei Zou, Stefania Izzo, Federica Grosso, Roberta Libener, Marco Loiacono, Valentina Monica, Consuelo Buttigliero,[...]. J Thorac Oncol 2018
37
27

Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
Aurélien de Reyniès, Marie-Claude Jaurand, Annie Renier, Gabrielle Couchy, Ilir Hysi, Nabila Elarouci, Françoise Galateau-Sallé, Marie-Christine Copin, Paul Hofman, Aurélie Cazes,[...]. Clin Cancer Res 2014
86
11

High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.
Yoshie Yoshikawa, Mitsuru Emi, Tomoko Hashimoto-Tamaoki, Masaki Ohmuraya, Ayuko Sato, Tohru Tsujimura, Seiki Hasegawa, Takashi Nakano, Masaki Nasu, Sandra Pastorino,[...]. Proc Natl Acad Sci U S A 2016
93
10

Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
Robert Ryan Meyerhoff, Chi-Fu Jeffrey Yang, Paul J Speicher, Brian C Gulack, Matthew G Hartwig, Thomas A D'Amico, David H Harpole, Mark F Berry. J Surg Res 2015
85
11

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Anna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, Chris Brown, Brett Gm Hughes, Deme J Karikios, Thomas John, Steven C-H Kao, Connull Leslie, Alistair M Cook,[...]. Lancet Oncol 2020
61
16

BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
Marta Cigognetti, Silvia Lonardi, Simona Fisogni, Piera Balzarini, Vilma Pellegrini, Andrea Tironi, Luisa Bercich, Mattia Bugatti, Giulio Rossi, Bruno Murer,[...]. Mod Pathol 2015
152
9

New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
F Galateau Salle, N Le Stang, A G Nicholson, D Pissaloux, A Churg, S Klebe, V L Roggli, H D Tazelaar, J M Vignaud, R Attanoos,[...]. J Thorac Oncol 2018
47
19

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Solenn Brosseau, Claire Danel, Arnaud Scherpereel, Julien Mazières, Sylvie Lantuejoul, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Valérie Gounant, Martine Antoine,[...]. Clin Lung Cancer 2019
35
25

Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.
Aaron S Mansfield, Tobias Peikert, James B Smadbeck, Julia B M Udell, Enrique Garcia-Rivera, Laura Elsbernd, Courtney L Erskine, Virginia P Van Keulen, Farhad Kosari, Stephen J Murphy,[...]. J Thorac Oncol 2019
61
14

Loss of BAP1 function leads to EZH2-dependent transformation.
Lindsay M LaFave, Wendy Béguelin, Richard Koche, Matt Teater, Barbara Spitzer, Alan Chramiec, Efthymia Papalexi, Matthew D Keller, Todd Hricik, Katerina Konstantinoff,[...]. Nat Med 2015
208
9

Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.
Min Zhang, Jin-Li Luo, Qianqian Sun, James Harber, Alan G Dawson, Apostolos Nakas, Sara Busacca, Annabel J Sharkey, David Waller, Michael T Sheaff,[...]. Nat Commun 2021
26
34

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Dean A Fennell, Sean Ewings, Christian Ottensmeier, Raffaele Califano, Gerard G Hanna, Kayleigh Hill, Sarah Danson, Nicola Steele, Mavis Nye, Lucy Johnson,[...]. Lancet Oncol 2021
35
25

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
Raunak Shrestha, Noushin Nabavi, Yen-Yi Lin, Fan Mo, Shawn Anderson, Stanislav Volik, Hans H Adomat, Dong Lin, Hui Xue, Xin Dong,[...]. Genome Med 2019
51
15


A conditional mouse model for malignant mesothelioma.
Johan Jongsma, Erwin van Montfort, Marc Vooijs, John Zevenhoven, Paul Krimpenfort, Martin van der Valk, Marc van de Vijver, Anton Berns. Cancer Cell 2008
87
9

EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
Andrew G Nicholson, Jennifer L Sauter, Anna K Nowak, Hedy L Kindler, Ritu R Gill, Martine Remy-Jardin, Samuel G Armato, Lynnette Fernandez-Cuesta, Raphael Bueno, Nicolas Alcala,[...]. J Thorac Oncol 2020
68
11

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
Vasiliki Panou, Meghana Gadiraju, Arthur Wolin, Caroline M Weipert, Emily Skarda, Aliya N Husain, Jyoti D Patel, Buerkley Rose, Shannon R Zhang, Madison Weatherly,[...]. J Clin Oncol 2018
87
9

Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.
Helen Yu, Helen Pak, Ian Hammond-Martel, Mehdi Ghram, Amélie Rodrigue, Salima Daou, Haithem Barbour, Luc Corbeil, Josée Hébert, Elliot Drobetsky,[...]. Proc Natl Acad Sci U S A 2014
217
8

Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.
Michele Carbone, J William Harbour, James Brugarolas, Angela Bononi, Ian Pagano, Anwesha Dey, Thomas Krausz, Harvey I Pass, Haining Yang, Giovanni Gaudino. Cancer Discov 2020
50
16

Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Marco Lo Iacono, Valentina Monica, Luisella Righi, Federica Grosso, Roberta Libener, Simona Vatrano, Paolo Bironzo, Silvia Novello, Loredana Musmeci, Marco Volante,[...]. J Thorac Oncol 2015
98
8

Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
G Pasello, G Zago, F Lunardi, L Urso, I Kern, G Vlacic, F Grosso, M Mencoboni, G L Ceresoli, M Schiavon,[...]. Ann Oncol 2018
50
16

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Luca Cantini, Raffit Hassan, Daniel H Sterman, Joachim G J V Aerts. Front Oncol 2020
30
26

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
Luana Calabrò, Aldo Morra, Diana Giannarelli, Giovanni Amato, Armida D'Incecco, Alessia Covre, Arthur Lewis, Marlon C Rebelatto, Riccardo Danielli, Maresa Altomonte,[...]. Lancet Respir Med 2018
126
8

The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
Francoise Galateau-Salle, Andrew Churg, Victor Roggli, William D Travis. J Thorac Oncol 2016
164
7

Novel therapies for malignant pleural mesothelioma.
Arnaud Scherpereel, Frederic Wallyn, Steven M Albelda, Camille Munck. Lancet Oncol 2018
82
8


Molecular pathogenesis of malignant mesothelioma.
Yoshitaka Sekido. Carcinogenesis 2013
148
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.